AGED Diagnostics: Interim Data & Two-Year Progress Review

​Join us for an inside look at AGED Diagnostics’ clinical progress, technology milestones, and traction as we advance the first noninvasive blood test to detect and stage MASH and liver fibrosis across the full disease spectrum.

​This session will include:
• Interim clinical data from our ongoing 500-patient, multi-site study (125+ patients enrolled to date)
• Two-year traction review across science, clinical execution, lab operations, and partnerships
• Bridge round overview ($250K committed toward a $1M raise) ahead of Series A (late 2026)

​We’ll walk through key inflection points, early performance indicators, and how we are preparing for future success.